Precision oncology's translation gap-Can molecular tumor boards bridge it?

Margaret M Byrne; Jill M Kolesar

doi:10.1371/journal.pmed.1005165

Back

Precision oncology's translation gap-Can molecular tumor boards bridge it?

Journal article

Open access

Peer reviewed

Precision oncology's translation gap-Can molecular tumor boards bridge it?

Margaret M Byrne and Jill M Kolesar

PLoS medicine, Vol.23(6), e1005165

06/2026

DOI: 10.1371/journal.pmed.1005165

PMID: 42378308

Files and links (1)

url

https://doi.org/10.1371/journal.pmed.1005165View

Published (Version of record) Open Access

Abstract

Precision oncology is revolutionizing cancer care, but isn't reaching enough patients. Molecular tumor boards (MTBs) translate complex genomic data to more effectively inform personalized care, and a new meta-analysis shows they boost clinical outcomes. But how can we feasibly and equitably expand the use of MTBs?

Humans

Medical Oncology - methods

Neoplasms - genetics

Neoplasms - therapy

Precision Medicine - methods

Translational Research, Biomedical

Details

Title: Subtitle: Precision oncology's translation gap-Can molecular tumor boards bridge it?
Creators: Margaret M Byrne - University of Iowa, Internal Medicine
Jill M Kolesar - University of Iowa
Resource Type: Journal article
Publication Details: PLoS medicine, Vol.23(6), e1005165
DOI: 10.1371/journal.pmed.1005165
PMID: 42378308
ISSN: 1549-1676
eISSN: 1549-1676
Publisher: PLOS
Language: English
Date published: 06/2026
Academic Unit: Pharmacy; Pharmaceutical Sciences and Experimental Therapeutics; Obstetrics and Gynecology; Internal Medicine
Record Identifier: 9985179098302771

Metrics

2 Record Views

See more details